Hong-My Nguyen

Hong-My Nguyen

Auto-generated profile, based on publicly available information

Hong-My Nguyen

Drug Safety Research & Development, Pfizer Inc, Groton, CT 06340, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in Molecular Therapy
Verified
Journal Article
Open access
HNHong-My Nguyen
Hong-My Nguyen
KAKristin E. Alexander
Kristin E. Alexander
MCMark Collinge
Mark Collinge
JHJames C. Hickey
James C. Hickey
TLThomas A. Lanz
Thomas A. Lanz
MTMitchell Thorn
Mitchell Thorn
RNA medicines have become a promising platform for therapeutic use in recent years. Understanding the immunomodulatory effects of novel mRNA-LNPs is crucial for future therapeutic development. An in vitro whole blood assay was developed to assess the impact of mRNA-LNPs on immune cell function, cytokine release, and complement activation. mRNA-LNPs significantly increased CD69 expression on T cells and natural killer (NK) cells, and CD80/CD86 on myeloid subsets, in a dose-dependent fashion. Furthermore, mRNA-LNPs elicited a robust release of pro-inflammatory cytokines, including TNF-α, IL-1β, MCP-1, IL-6, and IP-10, indicating a potent immune response. Notably, mRNA-LNPs stimulate early cytokine production prior to triggering immune cell activation, suggesting a temporal and biological relationship. Moreover, mRNA-LNPs induce complement activation via the alternative pathway, as evidenced by increased serum sC5b-9, C3a, and Bb which can amplify the inflammatory response and potentially impact safety. In vitro effects of mRNA-LNPs in whole blood of healthy human donors were compared to those from disease cohorts including systemic lupus erythematosus (SLE), type 2 diabetes mellitus (T2DM), and cancer donors. The differences in mRNA-LNPs effects on samples from healthy and diseased populations may impact therapeutic efficacy or toxicity, indicating a need for tailoring LNPs for specific target populations.

1 November 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
HNHong-My Nguyen
Hong-My Nguyen
PBPraveen K. Bommareddy
Praveen K. Bommareddy
ASAnn W. Silk
Ann W. Silk
DSDipongkor Saha
Dipongkor Saha